NCT05478226View on ClinicalTrials.gov

ADAMTSL4 in Idiopathic Pulmonary Hypertension and CTEPH

CompletedOBSERVATIONAL
Enrollment

67

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

August 31, 2020

Study Completion Date

July 1, 2022

Conditions
Pulmonary Hypertension
Interventions
OTHER

drugs or BPA

PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat

Trial Locations (1)

400016

the First Affiliated Hospital, Chongqing Medical University, Chongqing

All Listed Sponsors
lead

Wei Huang

OTHER

NCT05478226 - ADAMTSL4 in Idiopathic Pulmonary Hypertension and CTEPH | Biotech Hunter | Biotech Hunter